Possibility and prospects of using bamlanivimab in patients with COVID-19


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Currently, there is insufficient scientific evidence to recommend the routine use of bamlanivimab for the treatment of outpatients with COVID-19. An interim analysis of the phase II randomized placebo-controlled BLAZE-1 trial demonstrates the potential clinical benefit of bamlanivimab for outpatients with mild to moderate COVID-19, and its effectiveness in preventing the development of COVID-19 among medical personnel and residents of nursing homes.

全文:

受限制的访问

作者简介

K. Mirzaev

Russian Medical Academy of Continuous Professional Education

D. Sychev

Russian Medical Academy of Continuous Professional Education

参考

  1. FDA News Release. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19. Published November 9, 2020. (date of access: 22.12. 2020). URL: https://www.fda.gov/mvdia/143603/download
  2. Chen P, Nirula A., Heller B., et al; BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N EnglJ Med. Published on-line October 28, 2020. Doi: W.W56/NEJMoa202984-9.
  3. National Institutes of Health (NIH) News Release. Statement - NIH-sponsored ACTIV-3 trial closes LY-CoV555 sub-study. Published October 26, 2020. (date of access: 22.12.2020). URL: https://www.niaid.nih.gov/news-events/ statement-nih-sponsored-activ-3-trial-closes-ly-cov555-sub-study.
  4. URL: https://www.covid19treatmentgu'idelines. nih.gov/statement-on-bamlanivimab-eua
  5. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 (date of access: 28.12.2020). URL: https://www.idsociety.org/practice-guideline/ covid-19-guideline-treatment-and-management

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2021
##common.cookie##